# Pioneering Strategies to Unlocking the Potential of KRAS

By Healthcare · Published 2025-04-18 · Updated 2026-06-22 · Healthcare on MarketScale
Canonical: https://www.marketscale.com/industries/healthcare/pioneering-strategies-to-unlocking-the-potential-of-kras
Creator hub: Crown Bioscience

> Scientists are racing to overcome resistance mechanisms in newly approved KRAS therapies targeting the majority of difficult-to-treat cancers

## Key points

- KRAS mutations are prevalent in difficult-to-treat cancers like pancreatic, lung, and colorectal cancers.
- Recent FDA-approved KRAS G12C inhibitors mark significant strides but face resistance challenges.
- Preclinical models are critical for predicting clinical response and developing next-gen therapies.

Block Field

Once labeled "undruggable," **KRAS** has emerged as one of oncology's most promising—yet complex—targets. With nearly 90% of pancreatic cancers and 30-40% of lung and colorectal cancers harboring **KRAS** mutations, the need for effective therapies is urgent. Recent FDA approvals of [KRAS G12C](https://fightcolorectalcancer.org/blog/targeted-therapy-meets-immunotherapy/) inhibitors have signaled a new era, but the rise of resistance and diverse mutation profiles demand deeper innovation. As preclinical tools and combination strategies evolve, scientists must ask: how do we stay ahead of **KRAS**-driven resistance and translate insights into patient-specific treatment success?

> With nearly 90% of pancreatic cancers and 30-40% of lung and colorectal cancers harboring KRAS mutations, the need for effective therapies is urgent.

So, what will it take to overcome the final barriers to fully unlocking the therapeutic potential of **KRAS**?

In this episode of [*CrownCast*](https://marketscale.com/shows/crown-bioscience/), host [Jonny McMichael](https://www.linkedin.com/in/jonnymcmichael/), VP of Client Experience & Enablement at **Crown BioScience**, is joined by [Dr. Rajendra Kumari](https://www.linkedin.com/in/rajendra-kumari-85058028/), Executive Director of Integrated Solutions. Together, they delve into **KRAS** biology, resistance mechanisms, and preclinical strategies reshaping drug discovery. Their conversation touches on cutting-edge translational modeling and what the future holds for combination therapies targeting [KRAS mutations](https://www.cancer.gov/news-events/cancer-currents-blog/2022/kras-targeted-drugs-as-immunotherapy).

Key topics covered in this episode:

- 
Why **KRAS** mutations are uniquely challenging—and how recent breakthroughs have shifted the "undruggable" narrative.

- 
The rise of G12C inhibitors and how resistance is reshaping combination strategies in colorectal and lung cancer.

- 
The essential role of preclinical models, including engineered systems and [PDXs, in predicting clinical response and guiding next-gen drug development](https://blog.championsoncology.com/blog/accelerating-innovation-drug-development-with-pretreated-pdx-models).


### About the Guest

**Dr. Rajendra Kumari** brings over two decades of oncology research experience to **Crown BioScience**. A PhD in pharmacology from the University of Leicester, Jen co-founded preclinical CRO **PreCOS** in 2010, which was acquired by **Crown** in 2013. She has held various leadership roles including CSO, COO, and GM of Crown UK, and now leads global integrated solutions, driving innovation in translational modeling and oncology strategy.

Tags: Crown Bioscience, Dr. Rajendra Kumari, Jonny McMichael, KRAS G12C inhibitors, KRAS resistance, preclinical cancer models

---
Source: MarketScale, https://www.marketscale.com/industries/healthcare/pioneering-strategies-to-unlocking-the-potential-of-kras. Published for AI indexing and citation; cite the canonical URL. Site guide for agents: https://www.marketscale.com/llms.txt